Facultad de Ciencias Médicas y Biológicas "Dr. Ignacio Chávez", Universidad Michoacana de San Nicolás de Hidalgo, Morelia, Michoacán, Mexico.
Centro de Investigación Biomédica de Michoacán, Instituto Mexicano del Seguro Social, Morelia, Michoacán, Mexico.
PeerJ. 2024 Jul 30;12:e17817. doi: 10.7717/peerj.17817. eCollection 2024.
The intricate relationship between obesity and chronic kidney disease (CKD) progression underscores a significant public health challenge. Obesity is strongly linked to the onset of several health conditions, including arterial hypertension (AHTN), metabolic syndrome, diabetes, dyslipidemia, and hyperuricemia. Understanding the connection between CKD and obesity is crucial for addressing their complex interplay in public health strategies.
This research aimed to determine the prevalence of CKD in a population with high obesity rates and evaluate the associated metabolic risk factors.
In this cross-sectional study conducted from January 2017 to December 2019 we included 3,901 participants of both sexes aged ≥20 years who were selected from primary healthcare medical units of the Mexican Social Security Institute (IMSS) in Michoacan, Mexico. We measured the participants' weight, height, systolic and diastolic blood pressure, glucose, creatinine, total cholesterol, triglycerides, HDL-c, LDL-c, and uric acid. We estimated the glomerular filtration rate using the Collaborative Chronic Kidney Disease Epidemiology (CKD-EPI) equation.
Among the population studied, 50.6% were women and 49.4% were men, with a mean age of 49 years (range: 23-90). The prevalence of CKD was 21.9%. Factors significantly associated with an increased risk of CKD included age ≥60 years (OR = 11.70, 95% CI [9.83-15.93]), overweight (OR = 4.19, 95% CI [2.88-6.11]), obesity (OR = 13.31, 95% CI [11.12-15.93]), abdominal obesity (OR = 9.25, 95% CI [7.13-11.99]), AHTN (OR = 20.63, 95% CI [17.02-25.02]), impaired fasting glucose (IFG) (OR = 2.73, 95% CI [2.31-3.23]), type 2 diabetes (T2D) (OR = 14.30, 95% CI [11.14-18.37]), total cholesterol (TC) ≥200 mg/dL (OR = 6.04, 95% CI [5.11-7.14]), triglycerides (TG) ≥150 mg/dL (OR = 5.63, 95% CI 4.76-6.66), HDL-c <40 mg/dL (OR = 4.458, 95% CI [3.74-5.31]), LDL-c ≥130 mg/dL (OR = 6.06, 95% CI [5.12-7.18]), and serum uric acid levels ≥6 mg/dL in women and ≥7 mg/dL in men (OR = 8.18, 95% CI [6.92-9.68]), ( < 0.0001). These factors independently contribute to the development of CKD.
This study underscores the intricate relationship between obesity and CKD, revealing a high prevalence of CKD. Obesity, including overweight, abdominal obesity, AHTN, IFG, T2D, dyslipidemia, and hyperuricemia emerged as significant metabolic risk factors for CKD. Early identification of these risk factors is crucial for effective intervention strategies. Public health policies should integrate both pharmacological and non-pharmacological approaches to address obesity-related conditions and prevent kidney damage directly.
肥胖与慢性肾脏病(CKD)进展之间的复杂关系突显了重大的公共卫生挑战。肥胖与多种健康状况密切相关,包括动脉高血压(AHTN)、代谢综合征、糖尿病、血脂异常和高尿酸血症。了解 CKD 和肥胖之间的联系对于制定公共卫生策略中处理它们之间的复杂相互作用至关重要。
本研究旨在确定高肥胖率人群中 CKD 的患病率,并评估相关的代谢风险因素。
本横断面研究于 2017 年 1 月至 2019 年 12 月进行,纳入了来自墨西哥米却肯州墨西哥社会保障研究所(IMSS)初级保健医疗单位的 3901 名≥20 岁的男女参与者。我们测量了参与者的体重、身高、收缩压和舒张压、血糖、肌酐、总胆固醇、甘油三酯、HDL-c、LDL-c 和尿酸。我们使用协作慢性肾脏病流行病学(CKD-EPI)方程估计肾小球滤过率。
在所研究的人群中,50.6%为女性,49.4%为男性,平均年龄为 49 岁(范围:23-90)。CKD 的患病率为 21.9%。与 CKD 风险增加显著相关的因素包括年龄≥60 岁(OR=11.70,95%CI[9.83-15.93])、超重(OR=4.19,95%CI[2.88-6.11])、肥胖(OR=13.31,95%CI[11.12-15.93])、腹型肥胖(OR=9.25,95%CI[7.13-11.99])、AHTN(OR=20.63,95%CI[17.02-25.02])、空腹血糖受损(IFG)(OR=2.73,95%CI[2.31-3.23])、2 型糖尿病(T2D)(OR=14.30,95%CI[11.14-18.37])、总胆固醇(TC)≥200mg/dL(OR=6.04,95%CI[5.11-7.14])、甘油三酯(TG)≥150mg/dL(OR=5.63,95%CI[4.76-6.66])、HDL-c<40mg/dL(OR=4.458,95%CI[3.74-5.31])、LDL-c≥130mg/dL(OR=6.06,95%CI[5.12-7.18])和女性血清尿酸水平≥6mg/dL,男性血清尿酸水平≥7mg/dL(OR=8.18,95%CI[6.92-9.68]),(<0.0001)。这些因素独立导致 CKD 的发生。
本研究强调了肥胖与 CKD 之间的复杂关系,揭示了 CKD 的高患病率。肥胖症,包括超重、腹型肥胖、AHTN、IFG、T2D、血脂异常和高尿酸血症,是 CKD 的重要代谢危险因素。早期识别这些危险因素对于有效的干预策略至关重要。公共卫生政策应整合药物和非药物方法,以解决肥胖相关疾病,并直接预防肾脏损害。